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Last year marked the 10th annual meet-
ing of SCOPE, a group of dermatologists 
interested in skin care in organ trans-
plant recipients in Europe.* The need 
for this interest group stems from the 
increasing numbers of organ transplant 
recipients (OTRs) and their increasing 
longevity, which result in dramatically 
increased numbers of squamous cell 
carcinoma of the skin (SCC) and other 
benign and malignant skin conditions. 
SCOPE meetings have evolved to link 
a community of clinical dermatolo-
gists with basic researchers. Sixty par-
ticipants from Europe and the United 
States gathered for three days in Oslo, 
Norway, last June.
Tenderness of skin lesions was identi-
fied by Irma Wisgerhof (Leiden University 
Medical Center, The Netherlands) as a 
clinical clue to invasiveness of SCC. With 
a sensitivity of 40–70% and a specific-
ity of 75–88%, clinical tenderness was 
a close runner-up to clinical suspicion 
(diagnosis) by an expert dermatologist to 
identify invasive SCC in OTRs. Céleste 
Lebbé (Hôpital St Louis Paris, France) 
reported on high prevalence rates of 
Kaposi’s sarcoma (KS) in OTRs, paral-
leling the general seroprevalence for 
human herpesvirus 8 (HHV8), with age 
and African origin as major risk factors 
for KS. Catherine Harwood (Barts and 
the London School of Medicine, UK) and 
Charlotte Proby (Ninewells Hospital, 
University of Dundee, UK) reported a 
high cumulative SCC incidence—10, 
24, 54, and 73% at 5, 10, 20, and 30 
years following transplantation—in an 
ethnically diverse population of more 
than 1,000 renal transplant recipients 
(RTRs) in the United Kingdom. Risk fac-
tors for SCC were older age, Caucasian 
ethnicity, and male gender. Two-thirds of 
RTRs affected by SCC suffered multiple 
tumors, resulting in a considerable tumor 
burden. Seventy-four percent of all RTRs 
who had suffered a first SCC developed 
another SCC in the next 5 years. In the 
Asian RTRs, however, KS was the most 
prevalent skin neoplasm with second-
ary complications such as lymphedema. 
A differentiated schedule for dermato-
logical follow-up was suggested, on the 
basis of individual risk factors.
Skin cancer awareness was stud-
ied for its impact on prophylac-
tic behavior among RTRs by Beata 
Imko-Walczuk (Pomeranian Center, 
Gdansk, Poland). Only one-tenth of 
patients were aware of the relation-
ship between sun exposure and long-
term skin cancer formation under 
immuno suppression. Half of all RTRs 
never used sunscreens, pointing out an 
unmet medical need for sun-protection 
education. Basosquamous cell carci-
nomas in OTRs, described by Fanny 
Mougel (Hôpital Edouard Herriot, 
Lyon, France), occur in the head and 
neck area of OTRs along with a large 
number of other skin neoplasms, but 
without metastasis. Skin conditions 
after renal transplantation in child-
hood in Norway were summarized by 
Jan Sitek (Rijkshospitalet, Oslo), where 
kidneys from living donors make up an 
exceptionally high proportion (84%) of 
renal transplants. Pronounced hyper-
trichosis, gingival hyperplasia, and 
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striae were the most common skin 
changes observed. In RTRs less than 
18 years of age, no skin cancer was 
observed, but it occurred in low num-
bers at follow-up in adult life. Two or 
more melanocortin receptor type 1 
polymorphisms increase the odds for 
SCC in OTRs fourfold, reported Per 
Helsing (Rijkshospitalet), suggesting 
the use of genotyping as a tool to 
assess individual skin cancer risk in 
OTRs. Jean Kanitakis (Hôpital Edouard 
Herriot) focused on rejection in com-
posite tissue allografts (hands and face), 
suggesting that rejection is not antibody 
mediated, but rather driven by cellular 
activation, where Langerhans cells pop-
ulating the epidermis remain of donor 
origin and renew locally.
Human papilloma viruses (HPVs) 
and cutaneous SCC were reviewed by 
Ingo Nindl (German Cancer Research 
Center, Heidelberg). Increased preva-
lence and number of multiple infections 
of β/γ-HPV types were shown in OTRs, 
where HPV117 may play an active role 
in cutaneous wart formation and skin 
carcinogenesis. Frank Roesl (German 
Cancer Research Center) highlighted 
the mouse model of Mastomys coucha, 
which spontaneously develops 
SCC driven by mastomys natalensis 
papilloma virus. In this SCC model, 
virus-like particles were successfully 
used for a vaccination against SCC 
development. Acitretin holds prom-
ise for recalcitrant warts in OTRs, 
according to a contribution by Helena 
Gonzales (Dermatology Department, 
Gothenburg Hospital, Sweden).
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Nikol Mladkova (Barts and the 
London School of Medicine and 
Dentistry) confirmed a high preva-
lence for Merkel cell polyomavirus 
(MCPyV) in Merkel cell carcinoma, but 
also reported high prevalence rates for 
MCPyV nonmelanoma skin cancer and 
warts, raising questions as to the patho-
genic role for this newly discovered 
virus in OTRs. Trichodysplasia spinu-
losa is a rare condition in immuno-
compromised and leukemia patients, 
in relation to which Mariet Feltkamp 
(Leiden University Medical Center) 
presented a new cutaneous human 
polyomavirus, tentatively named 
trichodysplasia spinulosa-associated 
polyomavirus. Céleste Lebbé (Hôpital 
St. Louis) reported a high seroconversion 
rate for HHV8− recipients with HHV8+ 
grafts. A low incidence of HHV8 vire-
mia in OTRs, however, argues against 
routine HHV8 screening.
On the DNA level, common aber-
rations in SCC from OTRs were located 
by Nikol Mladkova on chromosomes 
3p and 9q. These aberrations were 
also found in sun-exposed but not 
in sun-protected skin. Jak-STAT and 
PPAR signaling pathways were acti-
vated in actinic keratosis versus 
sun-exposed skin, whereas mitogen-
activated protein kinase, Erb, and 
transforming-growth factor-β pathways 
were involved in actinic keratosis 
progression to SCC in OTRs.
Frank de Gruijl (Leiden University 
Medical Center) summarized the 
effects of rapamycin in a mouse 
model for UV-induced SCC, analo-
gous to the situation of OTRs in the 
human system. Here, rapamycin 
inhibits angio genesis and skin tumor 
growth but not SCC numbers in mice 
independent of p53. Günther Hofbauer 
(University Hospital Zurich) introduced 
ATF3 as an AP-1 family member that 
is specifically induced by calcineurin 
inhibitors, a mainstay of immunosup-
pressive regimens in OTR. ATF3 in 
turn suppresses p53 mRNA expression 
by direct binding to the p53 promoter. 
The resulting decrease in p53 expres-
sion favors uncontrolled growth and 
SCC formation of keratinocytes over 
keratino cyte senescence. This finding 
partially explains the greatly increased 
SCC formation under cyclosporin A in 
OTR. Interim data from a clinical trial of 
rapamycin against SCC in OTR suggests 
much lower SCC numbers compared 
with calcineurin inhibitors, as report-
ed by Sylvie Euvrard (Hôpital Edouard 
Herriot). Although final analysis is still 
pending, a switch from calcineurin 
inhibitors to rapamycin seems effective 
in cutting SCC formation.
MicroRNA expression in SCC anal-
yzed by Piotr Dziunycz (University 
Hospital Zurich) suggests different 
roles in miR regulation for UVA and 
UVB, well-known carcinogens for 
SCC formation. Per Arne Andresen 
(Rijkshospitalet) presented constitutive 
gene variants for TP53 and IL-10 for 
their potential as predictive markers 
in assessing the risk of SCC in RTRs. 
Irma Wisgerhof demonstrated patterns 
for subsequent SCC and basal cell car-
cinomas (BCCs) in kidney transplant 
recipients after a first skin cancer; SCC 
tended to be followed by SCC and BCC 
by BCC. Azathioprine increased the 
risk of SCC following SCC 2.5-fold. For 
BCC, living organ donation seemed to 
elevate risk 2.5-fold. Charlotte Proby 
(University of Dundee) summarized 
PTPRD deletions in association with 
metastatic cutaneous SCC. A micro-
deletion at 9p23–24, encoding for 
PTPRD, was inversely correlated with 
differentiation and associated with 
metastasis. Heterozygous missense 
mutations of PTPRD are common, 
whereas promoter methylation was not 
found in cutaneous SCC.
Mucosal Candida infection, which 
increases after transplantation, is 
dependent on oral prednisone dos-
age, as reported by Alexandra Geusau 
(Medical University of Vienna, Austria). 
Candida albicans seems easily con-
trolled in vitro, whereas Candida 
glabrata, Candida parapsilosis, and 
Candida krusei had higher rates of 
resistance. Almost two-thirds of all 
RTRs had at least one fungal agent 
identified compared with only one-
quarter in the control group in a Polish 
study by Beata Imko-Walczuk. Oral 
Candida colonization was the most 
frequent type, and toenails were the 
second most affected site. Karin Jahn 
(Medical University of Vienna) point-
ed out the uncommon presentation 
in organ transplantation of cicatricial 
pemphigoid of the Brunsting–Perry 
type. Clinical and dermatoscopic 
follow-up of acquired melanocytic 
nevi in OTRs studied by Deniz Seçkin 
(Baskent University, Ankara, Turkey) 
showed no impact on clinical and 
dermoscopic criteria consequent to 
immunosuppression.
*The 10th Annual Meeting of SCOPE was held 
at the Rijkshospitalet in Oslo, Norway, 10–12 
June 2010.
The 11th Annual Meeting of SCOPE will be 
hosted in Dundee, United Kingdom, by Charlotte 
Proby, 16–18 June 2011. Further information 
about SCOPE and its upcoming meeting is avail-
able at http://www.scopenetwork.org.
